14 insiders reported 37 Form 4 transactions for MBX Biosciences, Inc. (MBX) over the past 18 months (most recent 2026-05-11). Recent activity: Azoulay Salomon (Chief Medical Officer) Buy 55,000 shares, Azoulay Salomon (Chief Medical Officer) Sell 55,000 shares, Azoulay Salomon (Chief Medical Officer) Buy 15,003 shares, Azoulay Salomon (Chief Medical Officer) Sell 15,003 shares, Hawryluk P. Kent (President & CEO) Sell 607 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-11 | Azoulay Salomon | Chief Medical Officer | Buy | 55,000 | $575,300 |
| 2026-05-11 | Azoulay Salomon | Chief Medical Officer | Sell | 55,000 | $2.1M |
| 2026-05-11 | Azoulay Salomon | Chief Medical Officer | Buy | 15,003 | $240,048 |
| 2026-05-11 | Azoulay Salomon | Chief Medical Officer | Sell | 15,003 | $574,615 |
| 2026-05-08 | Hawryluk P. Kent | President & CEO | Sell | 607 | $17,931 |
| 2026-05-08 | Azoulay Salomon | Chief Medical Officer | Sell | 231 | $6,824 |
| 2026-03-16 | Hawryluk P. Kent | President & CEO | Buy | 18,500 | $525,585 |
| 2026-02-27 | Hawryluk P. Kent | President & CEO | Buy | 28,768 | $460,288 |
| 2026-02-03 | Bartram Richard | Chief Financial Officer | Buy | 15,000 | $0 |
| 2026-02-03 | Hawryluk P. Kent | President & CEO | Buy | 35,250 | $0 |
| 2026-02-03 | Azoulay Salomon | Chief Medical Officer | Buy | 15,000 | $0 |
| 2025-10-28 | Hawryluk P. Kent | President & CEO | Buy | 182,859 | $594,292 |
| 2025-10-21 | Hawryluk P. Kent | President & CEO | Buy | 20,000 | $272,800 |
| 2025-10-20 | Hoerter Steven L. | Director | Buy | 20,000 | $265,000 |
| 2025-09-30 | Heron Patrick J | Director | Buy | 666,666 | $12.0M |
| 2025-09-30 | Topper James N | Insider | Buy | 666,666 | $12.0M |
| 2025-09-30 | FHMLS X, L.L.C. | Insider | Buy | 666,666 | $12.0M |
| 2025-09-30 | Frazier Life Sciences X, L.P. | Insider | Buy | 666,666 | $12.0M |
| 2025-09-30 | FHMLS X, L.P. | Insider | Buy | 666,666 | $12.0M |
| 2025-04-10 | Pescovitz Ora H. | Director | Buy | 7,693 | $45,312 |
| 2025-02-19 | ORBIMED ADVISORS LLC | Director | Buy | 17,962 | $177,824 |
| 2025-02-19 | OrbiMed Capital GP VII LLC | Director | Buy | 17,962 | $177,824 |
| 2025-02-19 | OrbiMed Genesis GP LLC | Director | Buy | 17,962 | $177,824 |
| 2025-02-19 | ORBIMED ADVISORS LLC | Director | Buy | 29,540 | $290,969 |
| 2025-02-19 | OrbiMed Capital GP VII LLC | Director | Buy | 29,540 | $290,969 |
Source: SEC Form 4 filings · as of 2026-05-11